Feasibility Study of Gemcitabine Plus Docetaxel in Advanced or Recurrent Uterine Leiomyosarcoma and Undifferentiated Endometrial Sarcoma in Japan

Tadao Takano,Hitoshi Niikura,Kiyoshi Ito,Satoru Nagase,Hiroki Utsunomiya,Takeo Otsuki,Masafumi Toyoshima,Hideki Tokunaga,Michiko Kaiho-Sakuma,Naomi Shiga,Tomoyuki Nagai,Sota Tanaka,Ai Otsuki,Hiroki Kurosawa,Shogo Shigeta,Keita Tsuji,Takuhiro Yamaguchi,Nobuo Yaegashi

DOI: https://doi.org/10.1007/s10147-013-0627-5

2014-01-01

International Journal of Clinical Oncology

Abstract:Uterine leiomyosarcoma (LMS) and undifferentiated endometrial sarcoma (UES) are rare, aggressive malignancies. Both are treated similarly; however, few chemotherapy agents are effective. Recently, the combination of gemcitabine (900 mg/m2, days 1 and 8) plus docetaxel (100 mg/m2, day 8) with granulocyte colony-stimulating factor (G-CSF, 150 μg/m2, days 9–15) has been shown to have activity in LMS. In Japan, neither prophylactic G-CSF at a dose of 150 μg/m2 nor docetaxel at a dose of 100 mg/m2 are approved for use. For this reason, we evaluated the combination of 900 mg/m2 gemcitabine plus 70 mg/m2 docetaxel regimen without prophylactic G-CSF support in advanced or recurrent LMS and UES in Japanese patients.